A Phase 1 interventional study of 18F-AV-1451 and PET in Primary Progressive Aphasia With Suspected Alzheimer's Disease, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by University of Chicago · Phase 1, Interventional, and Diagnostic
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Exclusion Criteria:
Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
Drug: 18F-AV-1451 · Device: PET
Also known as: AV-1451
PET scanner for brain imaging
Tau levels in PPA participants
Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.
Time frame: 2 years
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Chicago